Sweden approves $223 million AZ TIKA sale
This article was originally published in Scrip
Executive Summary
Sweden's competition authority has approved the SEK1.8 billion ($222.9 million at current exchange rates) sale of AZ Tika, AstraZeneca's Nordic OTC portfolio, to GlaxoSmithKline.